Arsenic in India's water could cause resistance to visceral leishmaniasis treatment

October 29, 2013 by Marcia Malory report
Leishmaniasis ulcer on left forearm. Credit: Layne Harris / Wikipedia

(Medical Xpress)—Every year, visceral leishmaniasis infects about 500,000 people and kills about 41,000. Most deaths occur in India's Bihar region, where there is a high level of resistance to the antimony compounds used to treat this parasitic tropical disease. Alan Fairlamb and his colleagues at the University of Dundee have found that arsenic contamination of Bihar's water supply could be causing resistance to antimonial treatments. Their research appears in the Proceedings of the National Academy of Sciences.

The protozoa Leishmania donovani and Leishmania infantum cause by infecting the liver, spleen and bone marrow. Victims of the disease experience fever, anorexia, weight loss and inflammation of the liver and spleen. They will die without treatment. The only drugs that can kill the parasites that cause visceral leishmaniasis are antimonial preparations, amphotericin B, miltefosine, and paromomycin.

Doctors have been using antimonial drugs to treat visceral leishmaniasis successfully in sub-Saharan Africa and South America for almost 100 years. However, in Bihar, where most instances of the disease occur, cure rates using antimonial treatments had decreased to less than 50 percent by the end of the 20th century. Because of this, antimonial drugs are no longer the recommended treatment in India.

In the 1970s, engineers installed shallow tube wells in India to provide the population with clean . Subsequently, scientists discovered these wells exposed Biharis to arsenic by transferring naturally occurring arsenic in Bihar's groundwater to the domestic water supply. Fairlamb and his team thought arsenic in Bihar's domestic water supply could be causing to antimonial treatments for visceral leishmaniasis. Arsenic and antimony share similar chemical properties, and Bihar is the only region in the world where arsenic contaminates the drinking water, visceral leishmaniasis is endemic and there is widespread resistance to antimonial medicines.

To test their hypothesis, the researchers exposed mice to water laced with arsenic until the proportion of arsenic in the tissues of the mice was similar to that found in arsenic-exposed humans. They then infected the mice with Leishmania donovani. After a month, they euthanized the mice, recovered the parasites and then infected another group of -exposed mice. They repeated this process until the parasites had infected five groups of mice. With each successive group of , the Leishmania donovani became less sensitive to the antimonial drug Pentostam. By the time they had infected the final group, the parasites had become completely resistant to the drug.

Fairlamb and his team say their research reveals an urgent need for alternative sources of domestic water in India.

Explore further: Leishmania parasites with greater infectivity associated with treatment failure

More information: Chronic exposure to arsenic in drinking water can lead to resistance to antimonial drugs in a mouse model of visceral leishmaniasis, PNAS, Published online before print October 28, 2013, DOI: 10.1073/pnas.1311535110

Abstract
The Indian subcontinent is the only region where arsenic contamination of drinking water coexists with widespread resistance to antimonial drugs that are used to treat the parasitic disease visceral leishmaniasis. We have previously proposed that selection for parasite resistance within visceral leishmaniasis patients who have been exposed to trivalent arsenic results in cross-resistance to the related metalloid antimony, present in the pentavalent state as a complex in drugs such as sodium stibogluconate (Pentostam) and meglumine antimonate (Glucantime). To test this hypothesis, Leishmania donovani was serially passaged in mice exposed to arsenic in drinking water at environmentally relevant levels (10 or 100 ppm). Arsenic accumulation in organs and other tissues was proportional to the level of exposure and similar to that previously reported in human liver biopsies. After five monthly passages in mice exposed to arsenic, isolated parasites were found to be completely refractory to 500 μg⋅mL−1 Pentostam compared with the control passage group (38.5 μg⋅mL−1) cultured in vitro in mouse peritoneal macrophages. Reassessment of resistant parasites following further passage for 4 mo in mice without arsenic exposure showed that resistance was stable. Treatment of infected mice with Pentostam confirmed that resistance observed in vitro also occurred in vivo. We conclude that arsenic contamination may have played a significant role in the development of Leishmania antimonial resistance in Bihar because inadequate treatment with antimonial drugs is not exclusive to India, whereas widespread antimonial resistance is.

Related Stories

Leishmania parasites with greater infectivity associated with treatment failure

October 8, 2013
Relapses after treatment for Leishmania infection may be due to a greater infectivity of the parasite rather than drug resistance, as has been previously thought, according to a study published in mBio, the online open-access ...

Combination therapies are a cost-effective alternative when treating visceral leishmaniasis

September 16, 2013
Visceral leishmaniasis is the second-deadliest parasitic disease after malaria. Each year, thousands fall victim among poor and marginalised populations in low-income countries. Filip Meheus is the first to detail the economic ...

Kala-azar treatment failing in Nepal

March 1, 2013
In a recent study, scientists have concluded that the cure rates of Miltefosine, the only oral drug for visceral leishmaniasis available, have significantly decreased. Miltefosine was introduced in the Indian subcontinent ...

Human neutrophil peptide-1: A new anti-leishmanial drug candidate

October 17, 2013
Leishmaniasis is a vector borne disease caused by different Leishmania species with different clinical manifestations. Cutaneous leishmaniasis (CL) is endemic and widespread especially among young individuals in Iran. Currently ...

Old drug shows new promise to treat leishmaniasis

February 2, 2012
(Medical Xpress) -- A study published yesterday shows that a drug called fexinidazole could potentially be used to treat visceral leishmaniasis, a parasitic disease that kills 50 000 to 60 000 people a year in Africa, ...

Recommended for you

Google searches can be used to track dengue in underdeveloped countries

July 20, 2017
An analytical tool that combines Google search data with government-provided clinical data can quickly and accurately track dengue fever in less-developed countries, according to new research published in PLOS Computational ...

MRSA emerged years before methicillin was even discovered

July 19, 2017
Methicillin resistant Staphylococcus aureus (MRSA) emerged long before the introduction of the antibiotic methicillin into clinical practice, according to a study published in the open access journal Genome Biology. It was ...

New test distinguishes Zika from similar viral infections

July 18, 2017
A new test is the best-to-date in differentiating Zika virus infections from infections caused by similar viruses. The antibody-based assay, developed by researchers at UC Berkeley and Humabs BioMed, a private biotechnology ...

'Superbugs' study reveals complex picture of E. coli bloodstream infections

July 18, 2017
The first large-scale genetic study of Escherichia coli (E. coli) cultured from patients with bloodstream infections in England showed that drug resistant 'superbugs' are not always out-competing other strains. Research by ...

Ebola virus can persist in monkeys that survived disease, even after symptoms disappear

July 17, 2017
Ebola virus infection can be detected in rhesus monkeys that survive the disease and no longer show symptoms, according to research published by Army scientists in today's online edition of the journal Nature Microbiology. ...

Mountain gorillas have herpes virus similar to that found in humans

July 13, 2017
Scientists from the University of California, Davis, have detected a herpes virus in wild mountain gorillas that is very similar to the Epstein-Barr virus in humans, according to a study published today in the journal Scientific ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.